Makary Resigns as FDA Commissioner Following Policy Disputes - Takeaways - MDSpire

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

  • By

  • Kathryn Wighton

  • May 12, 2026

  • 2 min

Share

  • 1

    Marty Makary resigned as FDA Commissioner after 13 months, with Kyle Diamantas appointed as acting commissioner.

  • 2

    Makary's tenure included workforce reductions and significant turnover among senior FDA officials.

  • 3

    He opposed pediatric mask and vaccine mandates during the COVID-19 pandemic, criticizing CDC data reliance.

  • 4

    Makary focused on vaccine policy, food additive regulation, and dietary guidance, advocating for reduced processed food intake.

  • 5

    His resignation followed tensions over telehealth prescribing, regulatory review consistency, and flavored vaping product authorizations.

Original Source(s)

Makary Resigns as FDA Commissioner Following Policy Disputes

  • by Kathryn Wighton

  • May 12, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Top 10 Evidence-Based Essentials in Pathology

A structured framework of diagnostic classifications, reporting frameworks, staging systems, coding resources, and molecular pathology tools used in practice.

Do Revisions in Rotator Cuff Repair Decline With GLP-1 Use?

Preoperative use was associated with fewer revisions and no increase in short-term complications among patients with obesity, although benefits appeared concentrated in select subgroups.